Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Verywell Health on MSN17h
Novo Nordisk Offers Wegovy for $499 a Month in Direct-to-Consumer ProgramNovo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback